Skip to content

“An study to evaluate the efficacy of virechana(purgation) and basti (enema) followed by vishwadi dwadashanga kwatha (decoction) in the management of fibromyalgia ?.

“An open comparative clinical study to evaluate the efficacy of virechana karma and basti followed by vishwadi dwadashanga kwatha in the management of mamsagata vata w.s.r to fibromyalgia ?.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042676
Enrollment
30
Registered
2022-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M628- Other specified disorders of muscle

Interventions

None listed

Sponsors

National Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between 18 and 65 years of age. 2. Patients with the clinical features of Mamsagata Vata. 3. Patients with the clinical features of Fibromyalgia. 4. Patients fit for Virechana Karma and Niruha Basti. 5. Chronicity less than 10 years.

Exclusion criteria

Exclusion criteria: 1. Patient, suffering from any chronic debilitating disease like T.B., Varicose vein, Asthma, Rheumatoid Arthritis & other chronic problems etc. and having other serious pathology. 2. Patients suffering from systemic disorders as cardiac problem, uncontrolled Diabetes Mellitus, Uncontrolled Hypertension, Paralysis, Malignancy, HIV, HBsAg, Leprosy. 3. Pregnant women and lactating mother. 4. Associated with simple or compound fractures.

Design outcomes

Primary

MeasureTime frame
changes in American College of Rheumatology (ACR): Preliminary Criteria for FibromyalgiaTimepoint: assessment will be done on 0thday, 16th day, 31st day.

Secondary

MeasureTime frame
1. Changes in FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQ). 2. VAS-SCALE.: VAS have been recommended: no pain (0–4 mm), mild pain (5-44 mm), moderate pain (45–74 mm), and severe pain (75–100 mm) Timepoint: assessment will be done on 0thday, 16th day, 31st day.

Countries

India

Contacts

Public ContactDr SHALU RANI SINGHAL

National Institute of Ayurveda

gmangal108@gmail.com8619849011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026